Dear Members, The Board of Directors (Board) presents the annual report of Atul Ltd together with the audited Financial Statements for the year ended on March 31, 2025. 01. Financial results (` cr) Standalone Consolidated 2024-25 2023-24 2024-25 2023-24 Revenue from operations 5,075 4,358 5,583 4,726 Other income 133 134 109 58 Total income 5,208 4,492 5,692 4,784 Profit before tax 623 510 692 451 Tax expenses (167) (125) (193) (127) Profit for the year 456 385 499 324 Profit is attributable to: Owners of the Company 456 385 484 323 Non-controlling interests - - 15 1 Balance in retained earnings at the beginning of the year 4,356 4,107 4,340 4,153 Profit attributable to owners of the Company 456 385 484 323 Transfer from comprehensive income - - - - Buy-back of equity shares (net of amount adjusted from general reserve) - (62) - (62) Dividend (59) (74) (59) (74) Balance in retained earnings at the end of the year 4,753 4,356 4,765 4,340 Directors’ Report 02. Performance S tandalone revenue for the year at ` 5,075 cr increased by 16% compared to that of last year; the increase was mainly because of increase in volume. Sales increased by 16% in India and 17% outside India while sales volume increased by 15% and 17% respectively. Details about the two segments are given in Management Discussion and Analysis. Profit before tax (PBT) at ` 623 cr increased by 22% compared to that of last year mainly because of increase in sales volume and improved margins. Consolidated revenue for the year at ` 5,583 cr increased by 18% compared to that of last year. Sales of Life Science Chemicals (LSC) segment increased by 19% whereas those of Performance and Other Chemicals (POC) segment increased by 18%. PBT at ` 692 cr increased by 53% mainly because of increase in sales and better performance of the Group entities, like Amal Ltd (Amal), Atul Products Ltd (APL) and Rudolf Atul Chemicals Ltd (RACL). Amal (along with its 100% subsidiary company, Amal Speciality Chemicals Ltd) and RACL recorded their highest sales and PBT so far. APL, which had commissioned a new 300 TPD caustic soda manufacturing plant last year, further streamlined its operations — increased sales (from ` 65 cr) to ` 353 cr and increased EBITDA from ` 10 cr to ` 97 cr. Anaven LLP (Anaven), which operates one of the most modern Monochloroacetic acid manufacturing plants in the world, and the biggest in India — became EBITDA positive. However, it did not operate at optimum capacity due to lower product offtake. 03. Dividend The Board recommended dividend of ` 25 against last year ` 20 per equity share of ` 10 each fully paid-up for the year ended on March 31, 2025. The dividend will entail an outflow of ` 73.60 cr on the paid-up equity share capital of ` 29.44 cr. The payout was 16% against 15% last year. 48 Integrated Annual Report 2024-25 48
RkJQdWJsaXNoZXIy MjA2MDI2